Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

Recruiting in Palo Alto (17 mi)

+43 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: MacroGenics

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a combination of drugs that help the immune system fight cancer. It targets patients whose head and neck cancer has come back or spread. The treatment aims to make the body's defenses better at finding and destroying cancer cells. The study established the use of a specific drug, with or without additional treatment, for eligible patients with advanced head and neck cancer.

Research Team

Ashley L. Ward, MD

Principal Investigator

MacroGenics

Eligibility Criteria

Inclusion Criteria

Histologically proven, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) not curable by local therapy

Willing to consent for baseline and on-treatment biopsy.

Performance status 0 or 1

Treatment Details

Interventions

• Enoblituzumab (Monoclonal Antibodies)
• Retifanlimab (Monoclonal Antibodies)
• Tebotelimab (Monoclonal Antibodies)

Participant Groups

Group I: Tebotelimab Cohort Experimental Treatment 2 Interventions

Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles

Group II: Retifanlimab Cohort Experimental Treatment 2 Interventions

Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles

Who Is Running the Clinical Trial?

MacroGenics

Lead Sponsor

Trials

51

Recruited

5,400+